Analysts are on the Bearish side about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) this week.

September 8, 2018 - By Mary Kidd

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in 2018 Q1. Its down 0.25, from 1.22 in 2017Q4. It dropped, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Principal Fincl Group Inc Inc Inc stated it has 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). State Board Of Administration Of Florida Retirement reported 34,033 shares. 10,620 are held by Los Angeles Mgmt Equity Research Inc. Weiss Multi has 64,500 shares. 191,200 were accumulated by Alliancebernstein Ltd Partnership. Riggs Asset Managment Co reported 35 shares. Proshare Advisors Lc owns 37,696 shares. Jane Street Limited Liability Company invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Bnp Paribas Arbitrage invested in 0% or 17,582 shares. Moreover, Winslow Evans Crocker Inc has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Sphera Funds Mngmt Ltd stated it has 248,997 shares. Raymond James Associate owns 24,310 shares or 0% of their US portfolio. Chicago Equity Limited Liability holds 10,825 shares or 0.03% of its portfolio. Century reported 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Moreover, Renaissance Technologies Limited Company has 0.02% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 255,778 shares.

Since June 27, 2018, it had 1 insider purchase, and 2 selling transactions for $12.41 million activity. The insider Cumbo Alexander sold 33,782 shares worth $4.64M. The insider Barry Richard sold 75,000 shares worth $9.78 million.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 1 Hold. Therefore 93% are positive. Sarepta Therapeutics had 25 analyst reports since March 12, 2018 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Friday, May 4 with “Equal-Weight”. Oppenheimer downgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Thursday, May 3 to “Hold” rating. The firm earned “Equal-Weight” rating on Wednesday, March 21 by Morgan Stanley. Morgan Stanley maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Wednesday, June 20 with “Equal-Weight” rating. Leerink Swann maintained the shares of SRPT in report on Tuesday, March 13 with “Outperform” rating. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Thursday, June 21 by Nomura. The firm earned “Overweight” rating on Wednesday, March 14 by JP Morgan. Leerink Swann maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Wednesday, June 20. Leerink Swann has “Outperform” rating and $196 target. On Tuesday, May 15 the stock rating was maintained by Leerink Swann with “Buy”. As per Friday, May 4, the company rating was maintained by Credit Suisse. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

06/09/2018 Broker: Credit Suisse Rating: Outperform New Target: $178 Initiates Coverage On
01/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Old Target: $163 Upgrade
21/06/2018 Broker: Robert W. Baird Rating: Buy New Target: $202.0000 Maintain
21/06/2018 Broker: Nomura Old Rating: Buy New Rating: Buy Old Target: $131 New Target: $205 Maintain
20/06/2018 Broker: WBB Securities Rating: Buy Maintain
20/06/2018 Broker: Cowen & Co Rating: Buy New Target: $178.0000 Maintain
20/06/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $91 New Target: $163 Maintain
20/06/2018 Broker: Barclays Capital Rating: Buy New Target: $180.0000 Maintain
20/06/2018 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $121 New Target: $196 Maintain
19/06/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy Old Target: $96 New Target: $267 Maintain

The stock increased 0.89% or $1.26 during the last trading session, reaching $142.71. About 640,405 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since September 8, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.48 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Livetradingnews.com which released: “The Street’s Key Stock Analysts Research Reports” on September 07, 2018, also Globenewswire.com with their article: “Sarepta Therapeutics to Present at Two Upcoming Investor Conferences” published on September 04, 2018, Seekingalpha.com published: “Pfizer bails on DMD candidate domagrozumab” on August 30, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Seekingalpha.com and their article: “United Rentals Should Go Up – Cramer’s Lightning Round (8/16/18)” published on August 17, 2018 as well as Nasdaq.com‘s news article titled: “Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program” with publication date: August 20, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.